DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the publication of a paper in the October 15th issue of the Journal of Immunonology demonstrating that the Company’s proprietary RNA-electroporated dendritic cells generate high-avidity cytotoxic T cells (CTL) in vitro that are able to destroy cells expressing their target antigens. This advance may potentially improve the clinical benefit of dendritic cell-based immunotherapies for the treatment of infectious disease and cancer. This approach is part of the Company’s Arcelis™ technology, a proprietary platform for creating personalized immunotherapies for HIV, other infectious diseases, and cancer.
